References
- Speeckaert R, van Geel N, Vermaelen KV, et al. Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy. Pigment Cell Melanoma Res 2011;24(2):334-44
- Parmiani G, Maccalli C. The early antitumor immune response is necessary for tumor growth: re-visiting Prehn’s hypothesis in the human melanoma system. Oncoimmunology 2012;1(6):930-4
- Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev 2014;257(1):56-71
- Page DB, Postow MA, Callahan MK, Wolchok JD. Checkpoint modulation in melanoma: an update on ipilimumab and future directions. Curr Oncol Rep 2013;15(5):500-8
- Jacobs JF, Nierkens S, Figdor CG, et al. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol 2012;13(1):e32-42
- Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother 2012;61(2):255-63
- Clark WH Jr, Elder DE, Guerry D 4th, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81(24):1893-904
- Clemente CG, Mihm MC Jr, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77(7):1303-10
- Thomas NE, Busam KJ, From L, et al. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J Clin Oncol 2013;31(33):4252-9
- Hussein MR. Tumour-infiltrating lymphocytes and melanoma tumorigenesis: an insight. Br J Dermatol 2005;153(1):18-21
- Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol 2014;232(2):199-209
- Wang E, Bedognetti D, Marincola FM. Prediction of response to anticancer immunotherapy using gene signatures. J Clin Oncol 2013;31(19):2369-71
- Mann GJ, Pupo GM, Campain AE, et al. BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invest Dermatol 2013;133(2):509-17
- Schramm SJ, Campain AE, Scolyer RA, et al. Review and cross-validation of gene expression signatures and melanoma prognosis. J Invest Dermatol 2012;132(2):274-83
- GSK press release: Update on phase III clinical trial of investigational MAGE-A3 antigen-specific cancer immunotherapeutic in non-small cell lung cancer. 2014
- Mohos A, Sebestyen T, Liszkay G, et al. Immune cell profile of sentinel lymph nodes in patients with malignant melanoma – FOXP3+ cell density in cases with positive sentinel node status is associated with unfavorable clinical outcome. J Transl Med 2013;11:43-5876-11-43
- Nakamura R, Sakakibara M, Nagashima T, et al. Accumulation of regulatory T cells in sentinel lymph nodes is a prognostic predictor in patients with node-negative breast cancer. Eur J Cancer 2009;45(12):2123-31
- Kohrt HE, Nouri N, Nowels K, et al. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med 2005;2(9):e284
- Zuckerman NS, Yu H, Simons DL, et al. Altered local and systemic immune profiles underlie lymph node metastasis in breast cancer patients. Int J Cancer 2013;132(11):2537-47
- Vallacchi V, Vergani E, Camisaschi C, et al. Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30(+) T lymphocytes with progression. Cancer Res 2014;74(1):130-40